Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.

Merz M, Hielscher T, Schult D, Mai EK, Raab MS, Hillengass J, Seckinger A, Hose D, Granzow M, Jauch A, Goldschmidt H.

Leukemia. 2019 Nov 11. doi: 10.1038/s41375-019-0634-2. [Epub ahead of print] No abstract available.

PMID:
31712777
2.

Asymmetric distribution of TLR3 leads to a polarized immune response in human intestinal epithelial cells.

Stanifer ML, Mukenhirn M, Muenchau S, Pervolaraki K, Kanaya T, Albrecht D, Odendall C, Hielscher T, Haucke V, Kagan JC, Bartfeld S, Ohno H, Boulant S.

Nat Microbiol. 2019 Nov 4. doi: 10.1038/s41564-019-0594-3. [Epub ahead of print]

PMID:
31686029
3.

How to evaluate agreement between quantitative measurements.

Kopp-Schneider A, Hielscher T.

Radiother Oncol. 2019 Sep 25. pii: S0167-8140(19)33077-4. doi: 10.1016/j.radonc.2019.09.004. [Epub ahead of print]

PMID:
31563409
4.

The effect of gender-specific invitation letters on utilization of colorectal cancer screening.

Zhan T, Hielscher T, Eckardt M, Giese T, Schäfer C, Riemann JF, Ebert MP, Belle S.

Z Gastroenterol. 2019 Sep;57(9):1051-1058. doi: 10.1055/a-0958-2874. Epub 2019 Sep 16.

PMID:
31525797
5.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. No abstract available.

6.

Caspase-8 modulates physiological and pathological angiogenesis during retina development.

Tisch N, Freire-Valls A, Yerbes R, Paredes I, La Porta S, Wang X, Martín-Pérez R, Castro L, Wong WW, Coultas L, Strilic B, Gröne HJ, Hielscher T, Mogler C, Adams RH, Heiduschka P, Claesson-Welsh L, Mazzone M, López-Rivas A, Schmidt T, Augustin HG, Ruiz de Almodovar C.

J Clin Invest. 2019 Oct 22. pii: 122767. doi: 10.1172/JCI122767. [Epub ahead of print]

7.

Marginal variable screening for survival endpoints.

Edelmann D, Hummel M, Hielscher T, Saadati M, Benner A.

Biom J. 2019 Aug 26. doi: 10.1002/bimj.201800269. [Epub ahead of print]

PMID:
31448463
8.

Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.

Blocka J, Hielscher T, Mueller-Tidow C, Goldschmidt H, Hillengass J.

Leuk Lymphoma. 2019 Aug 19:1-10. doi: 10.1080/10428194.2019.1646905. [Epub ahead of print]

PMID:
31423866
9.

IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.

Röhrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, Windisch P, Hielscher T, Flechsig P, Floca R, Leitz D, Schuster JP, Huber PE, Debus J, von Deimling A, Lindner T, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2569-2580. doi: 10.1007/s00259-019-04444-y. Epub 2019 Aug 6.

PMID:
31388723
10.

Conditional Alox12b Knockout: Degradation of the Corneocyte Lipid Envelope in a Mouse Model of Autosomal Recessive Congenital Ichthyoses.

Krieg P, Dick A, Latzko S, Rosenberger S, Meyer J, Crumrine D, Hielscher T, Elias PM, Rauh M, Schneider H.

J Invest Dermatol. 2019 Jul 2. pii: S0022-202X(19)31850-0. doi: 10.1016/j.jid.2019.06.134. [Epub ahead of print] No abstract available.

PMID:
31276677
11.

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A.

J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5.

12.

Hypoxic Environment Promotes Barrier Formation in Human Intestinal Epithelial Cells through Regulation of MicroRNA 320a Expression.

Muenchau S, Deutsch R, de Castro IJ, Hielscher T, Heber N, Niesler B, Lusic M, Stanifer ML, Boulant S.

Mol Cell Biol. 2019 Jun 27;39(14). pii: e00553-18. doi: 10.1128/MCB.00553-18. Print 2019 Jul 15.

PMID:
31061092
13.

Rbpj expression in regulatory T cells is critical for restraining TH2 responses.

Delacher M, Schmidl C, Herzig Y, Breloer M, Hartmann W, Brunk F, Kägebein D, Träger U, Hofer AC, Bittner S, Weichenhan D, Imbusch CD, Hotz-Wagenblatt A, Hielscher T, Breiling A, Federico G, Gröne HJ, Schmid RM, Rehli M, Abramson J, Feuerer M.

Nat Commun. 2019 Apr 8;10(1):1621. doi: 10.1038/s41467-019-09276-w.

14.

Telomere length, arsenic exposure and risk of basal cell carcinoma of skin.

Srinivas N, Rachakonda S, Hielscher T, Calderazzo S, Rudnai P, Gurzau E, Koppova K, Fletcher T, Kumar R.

Carcinogenesis. 2019 Jul 6;40(6):715-723. doi: 10.1093/carcin/bgz059.

PMID:
30874287
15.

Susceptibility-weighted imaging in malignant melanoma brain metastasis.

Schwarz D, Niederle T, Münch P, Hielscher T, Hassel JC, Schlemmer HP, Platten M, Winkler F, Wick W, Heiland S, Delorme S, Bendszus M, Bäumer P, Breckwoldt MO.

J Magn Reson Imaging. 2019 Oct;50(4):1251-1259. doi: 10.1002/jmri.26692. Epub 2019 Feb 21.

PMID:
30793419
16.

The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma.

Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, Ridinger J, Riehl D, Usta D, Ismer B, Sommerkamp AC, Martinez-Barbera JP, Wefers AK, Remke M, Picard D, Pusch S, Gronych J, Oehme I, van Tilburg CM, Kool M, Kuhn D, Capper D, von Deimling A, Schuhmann MU, Herold-Mende C, Korshunov A, Brummer T, Pfister SM, Jones DTW, Witt O, Milde T.

Clin Cancer Res. 2019 Mar 15;25(6):1851-1866. doi: 10.1158/1078-0432.CCR-18-1965. Epub 2018 Dec 7.

PMID:
30530705
17.

Micronucleus formation in human cancer cells is biased by chromosome size.

Bochtler T, Kartal-Kaess M, Granzow M, Hielscher T, Cosenza MR, Herold-Mende C, Jauch A, Krämer A.

Genes Chromosomes Cancer. 2019 Jun;58(6):392-395. doi: 10.1002/gcc.22707. Epub 2019 Jan 17.

PMID:
30411433
18.

Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p.

Sievers P, Stichel D, Hielscher T, Schrimpf D, Reinhardt A, Wefers AK, Reuss D, Jones DTW, Bewerunge-Hudler M, Hartmann C, Baumgarten P, Wirsching HG, Winther-Kristensen B, Brokinkel B, Ketter R, Idoate Gastearena MA, Lamszus K, Seiz-Rosenhagen M, Mawrin C, Harter PN, Felsberg J, Hänggi D, Herold-Mende C, Berghoff AS, Weller M, Pfister SM, Wick W, Reifenberger G, Preusser M, von Deimling A, Sahm F.

Acta Neuropathol. 2018 Dec;136(6):975-978. doi: 10.1007/s00401-018-1924-x. Epub 2018 Oct 31. No abstract available.

PMID:
30382370
19.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

20.

Integrated molecular characterization of IDH-mutant glioblastomas.

Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M, Sharma T, Schrimpf D, Stichel D, Capper D, Reuss DE, Sturm D, Absalyamova O, Golanov A, Lambo S, Bewerunge-Hudler M, Lichter P, Herold-Mende C, Wick W, Pfister SM, Kool M, Jones DTW, von Deimling A, Sahm F.

Neuropathol Appl Neurobiol. 2019 Feb;45(2):108-118. doi: 10.1111/nan.12523. Epub 2018 Nov 15.

PMID:
30326163
21.

SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia.

Kraft B, Lombard J, Kirsch M, Wuchter P, Bugert P, Hielscher T, Blank N, Krämer A.

Leukemia. 2019 Mar;33(3):795-799. doi: 10.1038/s41375-018-0287-6. Epub 2018 Oct 15. No abstract available.

PMID:
30323357
22.

Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.

Berberich A, Kessler T, Thomé CM, Pusch S, Hielscher T, Sahm F, Oezen I, Schmitt LM, Ciprut S, Hucke N, Ruebmann P, Fischer M, Lemke D, Breckwoldt MO, von Deimling A, Bendszus M, Platten M, Wick W.

Clin Cancer Res. 2019 Jan 1;25(1):253-265. doi: 10.1158/1078-0432.CCR-18-1580. Epub 2018 Oct 1.

PMID:
30274984
23.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21.

PMID:
30131584
24.

Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients.

Berberich A, Hielscher T, Kickingereder P, Winkler F, Drüschler K, Riedemann L, Arzt M, Kessler T, Platten M, von Deimling A, Wick W, Sahm F, Bendszus M, Wick A.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1472-1480. doi: 10.1016/j.ijrobp.2018.07.2004. Epub 2018 Jul 31.

PMID:
30071292
25.

Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI.

Karimian-Jazi K, Wildemann B, Diem R, Schwarz D, Hielscher T, Wick W, Bendszus M, Breckwoldt MO.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 16;5(5):e480. doi: 10.1212/NXI.0000000000000480. eCollection 2018 Sep.

26.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Dec;32(12):2717-2719. doi: 10.1038/s41375-018-0202-1. Epub 2018 Jul 6. No abstract available.

PMID:
29977018
27.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. No abstract available.

PMID:
29959413
28.

Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.

Wennmann M, Kintzelé L, Piraud M, Menze BH, Hielscher T, Hofmanninger J, Wagner B, Kauczor HU, Merz M, Hillengass J, Langs G, Weber MA.

Oncotarget. 2018 May 18;9(38):25254-25264. doi: 10.18632/oncotarget.25402. eCollection 2018 May 18.

29.

Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.

Röhrich M, Huang K, Schrimpf D, Albert NL, Hielscher T, von Deimling A, Schüller U, Dimitrakopoulou-Strauss A, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1573-1584. doi: 10.1007/s00259-018-4009-0. Epub 2018 May 7.

PMID:
29732524
30.

Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.

Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F.

Acta Neuropathol. 2018 Jun;135(6):955-963. doi: 10.1007/s00401-018-1844-9. Epub 2018 Apr 7.

PMID:
29627952
31.

A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.

Wirthschaft P, Bode J, Simon AEM, Hoffmann E, van Laack R, Krüwel T, Dietrich F, Bucher D, Hahn A, Sahm F, Breckwoldt MO, Kurz FT, Hielscher T, Fischer B, Dross N, Ruiz de Almodovar C, von Deimling A, Herold-Mende C, Plass C, Boulant S, Wiestler B, Reifenberger G, Lichter P, Wick W, Tews B.

Int J Cancer. 2018 Sep 1;143(5):1176-1187. doi: 10.1002/ijc.31404. Epub 2018 Apr 16.

32.

Toward an integrated map of genetic interactions in cancer cells.

Rauscher B, Heigwer F, Henkel L, Hielscher T, Voloshanenko O, Boutros M.

Mol Syst Biol. 2018 Feb 21;14(2):e7656. doi: 10.15252/msb.20177656.

33.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

34.

Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis.

Jennemann R, Federico G, Mathow D, Rabionet M, Rampoldi F, Popovic ZV, Volz M, Hielscher T, Sandhoff R, Gröne HJ.

Oncotarget. 2017 Nov 24;8(65):109201-109216. doi: 10.18632/oncotarget.22648. eCollection 2017 Dec 12.

35.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2018 Jan 9;2(1):1-9. doi: 10.1182/bloodadvances.2017013334.

PMID:
31248901
36.

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.

Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J.

Haematologica. 2018 Feb;103(2):336-343. doi: 10.3324/haematol.2017.176073. Epub 2017 Dec 7.

37.

Invitation letters increase participation in colorectal cancer screening - results from an observational study.

Zhan T, Hielscher T, Bilge A, Giese T, Schäfer C, Riemann JF, Ebert MP, Belle S.

Z Gastroenterol. 2017 Dec;55(12):1307-1312. doi: 10.1055/s-0043-121347. Epub 2017 Dec 6.

PMID:
29212101
38.

[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Brandelik SC, Krzykalla J, Hielscher T, Hillengass J, Kloth JK, Kauczor HU, Weber MA.

Radiologe. 2018 Jan;58(1):72-78. doi: 10.1007/s00117-017-0299-7. German.

PMID:
28905085
39.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

40.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
41.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15. No abstract available.

42.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.

43.

Hyperosmolarity impedes the cross-priming competence of dendritic cells in a TRIF-dependent manner.

Popovic ZV, Embgenbroich M, Chessa F, Nordström V, Bonrouhi M, Hielscher T, Gretz N, Wang S, Mathow D, Quast T, Schloetel JG, Kolanus W, Burgdorf S, Gröne HJ.

Sci Rep. 2017 Mar 22;7(1):311. doi: 10.1038/s41598-017-00434-y.

44.

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A.

Lancet Oncol. 2017 May;18(5):682-694. doi: 10.1016/S1470-2045(17)30155-9. Epub 2017 Mar 15.

45.

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.

Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, Fulda S, Witt O, Eggert A, Fischer M, Deubzer HE.

Cell Death Dis. 2017 Mar 2;8(3):e2635. doi: 10.1038/cddis.2017.49.

46.

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Marquardt V, Pauck D, Bächli H, Stiles CD, von Deimling A, Remke M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, Milde T.

Oncotarget. 2017 Feb 14;8(7):11460-11479. doi: 10.18632/oncotarget.14004.

47.

Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.

Breckwoldt MO, Gradl J, Hähnel S, Hielscher T, Wildemann B, Diem R, Platten M, Wick W, Heiland S, Bendszus M.

J Neurol. 2017 Feb;264(2):341-349. doi: 10.1007/s00415-016-8353-3. Epub 2016 Dec 1.

PMID:
27909801
48.

Multiple behavioral factors are associated with occurrence of large, flat colorectal polyps.

Zhan T, Hahn F, Hielscher T, Bilge A, Grüger J, Weers J, Betge J, Gaiser T, Kähler G, Ebert MP, Belle S.

Int J Colorectal Dis. 2017 Apr;32(4):575-582. doi: 10.1007/s00384-016-2717-0. Epub 2016 Nov 28.

PMID:
27896421
49.

Prognostic relevance of miRNA-155 methylation in anaplastic glioma.

Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiß EK, Weiler M, Baer C, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein A, Roth P, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel MC, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten M, Weller M, Plass C, Wick W.

Oncotarget. 2016 Dec 13;7(50):82028-82045. doi: 10.18632/oncotarget.13452.

50.

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.

Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.

Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.

Supplemental Content

Loading ...
Support Center